Related Experiment Video
Updated: Jun 19, 2025
Isolation of Human Atrial Myocytes for Simultaneous Measurements of Ca2+ Transients and Membrane Currents
Published on: July 3, 2013
Beneficial Effect of Calcium Treatment for Hyperkalemia Is Not Due to "Membrane Stabilization"
Joseph S Piktel1, Xiaoping Wan2, Shalen Kouk3
1Department of Emergency Medicine, Emergency Care and Research and Innovation, MetroHealth Campus, Case Western Reserve University, Cleveland, OH.
Insights
Calcium (Ca 2+ ) treatment for hyperkalemia restores cardiac conduction via calcium-dependent pathways, not by stabilizing the membrane potential. This finding clarifies the mechanism behind calcium
Area of Science:
- Cardiovascular Physiology
- Electrophysiology
- Medical Research
Background:
- Hyperkalemia is a critical condition causing dangerous electrophysiologic disturbances and arrhythmias.
- The mechanism of calcium (Ca 2+ )'s beneficial effect in hyperkalemia, often attributed to membrane stabilization, is not fully understood.
Purpose of the Study:
- To investigate the electrophysiologic effects of hyperkalemia.
- To elucidate the therapeutic mechanisms of Ca 2+ treatment in hyperkalemia.
Main Methods:
- A controlled experimental trial using canine myocytes and tissue preparations.
- Recorded optical action potentials and electrocardiograms during varying potassium and Ca 2+ concentrations.
- Measured resting membrane potential (RMP) in isolated myocytes.
Main Results:
- Hyperkalemia significantly slowed conduction velocity (CV) and shortened action potential duration (APD), leading to QRS widening and sine wave patterns.
- Ca 2+ treatment restored CV and normalized electrocardiograms but did not restore APD or RMP.
- The therapeutic effect of Ca 2+ was diminished by L-type Ca 2+ channel blockade, indicating Ca 2+ -dependent conduction.
Conclusions:
- Ca 2+ treatment restores conduction in hyperkalemia through Ca 2+ -dependent propagation, not membrane stabilization.
- Findings provide a mechanistic basis for using Ca 2+ to treat conduction abnormalities in hyperkalemia.
Objectives:
Hyperkalemia is a common life-threatening condition causing severe electrophysiologic derangements and arrhythmias. The beneficial effects of calcium (Ca 2+ ) treatment for hyperkalemia have been attributed to "membrane stabilization," by restoration of resting membrane potential (RMP). However, the underlying mechanisms remain poorly understood. Our objective was to investigate the mechanisms underlying adverse electrophysiologic effects of hyperkalemia and the therapeutic effects of Ca 2+ treatment.
Design:
Controlled experimental trial.
Setting:
Laboratory investigation.
Subjects:
Canine myocytes and tissue preparations.
Interventions And Measurements:
Optical action potentials and volume averaged electrocardiograms were recorded from the transmural wall of ventricular wedge preparations ( n = 7) at baseline (4 mM potassium), hyperkalemia (8-12 mM), and hyperkalemia + Ca 2+ (3.6 mM). Isolated myocytes were studied during hyperkalemia (8 mM) and after Ca 2+ treatment (6 mM) to determine cellular RMP.
Main Results:
Hyperkalemia markedly slowed conduction velocity (CV, by 67% ± 7%; p < 0.001) and homogeneously shortened action potential duration (APD, by 20% ± 10%; p < 0.002). In all preparations, this resulted in QRS widening and the "sine wave" pattern observed in severe hyperkalemia. Ca 2+ treatment restored CV (increase by 44% ± 18%; p < 0.02), resulting in narrowing of the QRS and normalization of the electrocardiogram, but did not restore APD. RMP was significantly elevated by hyperkalemia; however, it was not restored with Ca 2+ treatment suggesting a mechanism unrelated to "membrane stabilization." In addition, the effect of Ca 2+ was attenuated during L-type Ca 2+ channel blockade, suggesting a mechanism related to Ca 2+ -dependent (rather than normally sodium-dependent) conduction.
Conclusions:
These data suggest that Ca 2+ treatment for hyperkalemia restores conduction through Ca 2+ -dependent propagation, rather than restoration of membrane potential or "membrane stabilization." Our findings provide a mechanistic rationale for Ca 2+ treatment when hyperkalemia produces abnormalities of conduction (i.e., QRS prolongation).
More Related Videos
Related Concept Videos
01:28Antihypertensive Drugs: Potassium-Sparing Diuretics
01:20Antiarrhythmic Drugs: Class IV Agents as Calcium Channel Blockers
Verapamil, a calcium channel blocker, inhibits calcium movement across myocardial cell membranes and vascular smooth muscle. This results in the dilation of coronary and...
01:18Antihypertensive Drugs: Action of Calcium Channel Blockers
01:12Antiarrhythmic Drugs: Class III Agents as Potassium Channel Blockers
01:17Antiepileptic Drugs: Calcium Channel Blockers
Calcium channel blockers exert their antiepileptic effects by targeting T-type calcium channels, which are integral to transmitting nerve signals in the central nervous system. These channels allow the passage of calcium ions, which are vital for neuronal communication. By inhibiting T-type calcium channels, calcium channel blockers effectively reduce the release of neurotransmitters and...
01:26Heart Failure Drugs: Inotropic Agents